Volociximab

{{Short description|Monoclonal antibody}}

{{Drugbox

| Verifiedfields = changed

| Watchedfields = changed

| verifiedrevid = 470631639

| image =

| type = mab

| mab_type = mab

| source = xi/o

| target = α5β1 integrin

| tradename =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category =

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| legal_status =

| routes_of_administration =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}

| ChemSpiderID = none

| CAS_number_Ref = {{cascite|changed|??}}

| CAS_number = 558480-40-3

| ATC_prefix = none

| ATC_suffix =

| PubChem =

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank =

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = 496K5Z02NW

| KEGG_Ref = {{keggcite|correct|kegg}}

| KEGG = D06319

| C=6434 | H=9942 | N=1706 | O=2040 | S=52

}}

Volociximab (also known as M200) is a chimeric monoclonal antibody jointly developed by PDL BioPharma and Biogen Idec for treatment of a variety of advanced solid tumors. It binds to and inhibits the functional activity of α5β1 integrin.{{cite journal | vauthors = Ng CM, Bai S, Takimoto CH, Tang MT, Tolcher AW | title = Mechanism-based receptor-binding model to describe the pharmacokinetic and pharmacodynamic of an anti-α5β1 integrin monoclonal antibody (volociximab) in cancer patients | journal = Cancer Chemotherapy and Pharmacology | volume = 65 | issue = 2 | pages = 207–17 | date = January 2010 | pmid = 19468731 | doi = 10.1007/s00280-009-1023-8 | s2cid = 23035675 }}

It is thought to reduce metastases. Early results show potential in renal cell cancers.{{citation needed|date=April 2016}}